Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma

Next Previous
Trial Profile

REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms REFINE
  • Sponsors Bayer

    • Most Recent Events

    • 20 Jan 2024 Results of subgroup analysis of patients with unresectable hepatocellular carcinoma and Child-Pugh-B liver function treated with regorafenib in routine clinical practice presented at the 2024 Gastrointestinal Cancers Symposium.
    • 24 Oct 2023 Final analysis (n=1005) of this study confirming the safety and effectiveness of regorafenib (REG) in patients prior liver transplantation (PLT) with unresectable hepatocellular carcinoma (uHCC) presented at the 48th European Society for Medical Oncology Congress.
    • 12 Oct 2023 According to a Bayer media release, the company will highlight data from this study will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain from October 20-24, 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top